Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Bushinsky

Showing results (91-100 of 128) with videos related to

Pageof 13
Sort By:
Genetics|May 5, 2012
Sex modifies genetic effects on residual variance in urinary calcium excretion in rat (Rattus norvegicus)Guy M L Perry, Keith W Nehrke, David A Bushinsky, et al.
American Journal of Nephrology|October 27, 2016
Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on HemodialysisDavid A Bushinsky, Patrick Rossignol, David M Spiegel, et al.
Kidney International|February 19, 2002
Calcium oxalate stone formation in genetic hypercalciuric stone-forming ratsDavid A Bushinsky, John R Asplin, Marc D Grynpas, et al.
Journal of the American Society of Nephrology : JASN|February 22, 2003
The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal diseaseL Darryl Quarles, Donald J Sherrard, Stephen Adler, et al.
Journal of the American Society of Nephrology : JASN|April 10, 2015
Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of HypercalciuriaNancy S Krieger, John R Asplin, Kevin K Frick, et al.
Kidney International Reports|July 19, 2019
Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis PatientsJohn Cunningham, Geoffrey A Block, Glenn M Chertow, et al.
European Journal of Heart Failure|October 14, 2015
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitorsBertram Pitt, George L Bakris, David A Bushinsky, et al.
The American Journal of Medicine|November 29, 2017
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS InhibitorsMatthew R Weir, David A Bushinsky, Wade W Benton, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 6, 2017
Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKDDavid A Bushinsky, Thomas Hostetter, Gerrit Klaerner, et al.
JAMA|July 15, 2015
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical TrialGeorge L Bakris, Bertram Pitt, Matthew R Weir, et al.
Pageof 13

Showing results (91-100 of 128) with videos related to

Sort By:
Pageof 13
Genetics|May 5, 2012
Sex modifies genetic effects on residual variance in urinary calcium excretion in rat (Rattus norvegicus)Guy M L Perry, Keith W Nehrke, David A Bushinsky, et al.
American Journal of Nephrology|October 27, 2016
Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on HemodialysisDavid A Bushinsky, Patrick Rossignol, David M Spiegel, et al.
Kidney International|February 19, 2002
Calcium oxalate stone formation in genetic hypercalciuric stone-forming ratsDavid A Bushinsky, John R Asplin, Marc D Grynpas, et al.
Journal of the American Society of Nephrology : JASN|February 22, 2003
The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal diseaseL Darryl Quarles, Donald J Sherrard, Stephen Adler, et al.
Journal of the American Society of Nephrology : JASN|April 10, 2015
Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of HypercalciuriaNancy S Krieger, John R Asplin, Kevin K Frick, et al.
Kidney International Reports|July 19, 2019
Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis PatientsJohn Cunningham, Geoffrey A Block, Glenn M Chertow, et al.
European Journal of Heart Failure|October 14, 2015
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitorsBertram Pitt, George L Bakris, David A Bushinsky, et al.
The American Journal of Medicine|November 29, 2017
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS InhibitorsMatthew R Weir, David A Bushinsky, Wade W Benton, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 6, 2017
Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKDDavid A Bushinsky, Thomas Hostetter, Gerrit Klaerner, et al.
JAMA|July 15, 2015
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical TrialGeorge L Bakris, Bertram Pitt, Matthew R Weir, et al.
Pageof 13